reports
Iradimed Corp: 1 director
A director at Iradimed Corp sold 7,500 shares at 100.063USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
MGM Resorts International: 1 director
A director at MGM Resorts International sold 37,500 shares at 34.270USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Ligand Pharmaceuticals Inc: 2 directors
Two Directors at Ligand Pharmaceuticals Inc sold after exercising options/sold 18,423 shares at between 205.828USD and 206.354USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trad...
Peabody Energy Corp: 1 director
A director at Peabody Energy Corp sold/sold after exercising options 30,000 shares at 35.580USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
Occidental Announces Total Consideration for its Cash Tender Offers an...
Occidental Announces Total Consideration for its Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced the consideration payable in respect of its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its Zero Coupon Senior Notes due 2036 (the “0.000% 2036 Notes”), 6.125% Senior Notes due 2031 (the “6.125% 2031 Notes”), 6.625% Senior Notes due 2030 (the “6.625% 2030 Notes”), 7.200% Debentures due 2029 (the “7.200% 2029 Debentures”) and 7.950% D...
Occidental Announces Early Tender Results and Upsize in Cash Tender Of...
Occidental Announces Early Tender Results and Upsize in Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced the early tender results, as set forth in the table below, of its offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its Zero Coupon Senior Notes due 2036 (the “0.000% 2036 Notes”), 6.125% Senior Notes due 2031 (the “6.125% 2031 Notes”), 6.625% Senior Notes due 2030 (the “6.625% 2030 Notes”), 7.200% Debentures due 2029 (the “7.200% 2...
Angi Launches the Angi App in ChatGPT
Angi Launches the Angi App in ChatGPT New app guides homeowners from question to contractors — moving from conversational AI recommendations in ChatGPT to matching with skilled pros on Angi DENVER, March 04, 2026 (GLOBE NEWSWIRE) -- As homeowners increasingly turn to AI to start home projects, (formerly Angie’s List) (NASDAQ: ANGI), a leading digital home services marketplace, today announced the launch of the Angi app in ChatGPT. This app enables homeowners to move from asking a home-improvement question in ChatGPT to connecting directly with a skilled pro on Angi. Angi is among the f...
Ligand to Participate in March Investor Conferences
Ligand to Participate in March Investor Conferences JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami): Management will participate in one-on-one meetings March 11, 202638th Annual ROTH Conference (Dana Point, Calif.): Management will present at 1:00 p.m. PT on March 23, 2026Nordic-American Healthcare Conference 2026 (New York): Management will present at 3:45 p.m. ET on Mar...
OPKO Health to Participate in the Jefferies Biotech on the Beach Summi...
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th. Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative. About OPKO Health OPKO is a multinational biopharmaceutic...
Macerich Closes Amended and Restated $900 Million Revolving Credit Fac...
Macerich Closes Amended and Restated $900 Million Revolving Credit Facility SANTA MONICA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) (the “Company” or “Macerich”), a leading owner, operator, and developer of major retail properties in top markets, today announced that it has closed an amended and restated $900 million revolving credit facility. “We are pleased to close on this new facility, which enhances our liquidity, provides additional flexibility, extends the maturity term, lowers pricing, reduces unused commitment fees, and expands our lending group,...
Turtle Beach Corporation to Report Fourth Quarter & Full Year 2025 Fin...
Turtle Beach Corporation to Report Fourth Quarter & Full Year 2025 Financial Results on Thursday, March 12, 2026 SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: TBCH) a leading gaming accessories brand, today announced it will report financial results for the fourth quarter and full year 2025 on Thursday, March 12, 2026, after the close of trading on the Nasdaq Stock Market. The Company will also host a conference call and audio webcast at 5:00p.m. ET / 2:00p.m. PT that same day to review the results. The call will be hosted by Cris Keirn, Chief Executive Officer, and Mark Weinswi...
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financ...
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This n...
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results Robust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8.00-$9.00 Conference call and webcast at 8:30 a.m. Eastern time today JUPITER, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2025, and provided an operating forecast and business update. Ligand man...
Macerich to Present at Citi’s 2026 31st Annual Global Property CEO Con...
Macerich to Present at Citi’s 2026 31st Annual Global Property CEO Conference SANTA MONICA, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) (the “Company” or “Macerich”) today announced that Jack Hsieh, President and Chief Executive Officer, and Dan Swanstrom, Senior Executive Vice President and Chief Financial Officer, will participate in a round table presentation at Citi’s 2026 Global Property CEO Conference on Monday, March 2, 2026, at 2:55 PM Eastern Time. A live audio can be accessed from the Investors section of the Company’s website, , and a replay wil...
Texas Pacific Land Corp: 1 director
A director at Texas Pacific Land Corp sold/sold after exercising options 1,608 shares at 503.000USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care ConferenceFireside Chat: Monday, March 2, 2026, at 3:10 p.m. ET in Boston, MA Leerink Partners Global Healthcare ConferenceFireside Chat: Monday, March 9, 2026, at 4:20 p.m. ET in Miami Beach, FL The C...
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in...
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the CLARITY Phase 3 trial of solriamfetol in the treatment of major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms. CLARITY (Clinical Assessment of Response in the T...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financia...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively,representing 68% and 74% year-over-year growth SUNOSI® 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively,representing 40% and 32% year-over-year growth SYMBRAVO® 4Q and full year 2025 net product sal...
Occidental Announces Cash Tender Offers and Consent Solicitations for ...
Occidental Announces Cash Tender Offers and Consent Solicitations for Certain of its Senior Notes and Debentures HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced that it has commenced offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”) its outstanding senior notes and debentures listed in the table below and Consent Solicitations (as defined below) with respect to certain series of such senior notes and debentures, upon the terms and conditions described in Occidental’s Offer to Purchase and Consent Solicitation Statement, dated...
Occidental Announces Fourth Quarter 2025 Results
Occidental Announces Fourth Quarter 2025 Results HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced its fourth quarter 2025 financial results. The earnings release and accompanying financial schedules can be accessed via the section of the company’s website at . The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Thursday, February 19, 2026, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (internat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.